Determination of Serum Prostate Specific Antigen Levels Amongst Apparently Healthy Nigerian Males in a University and University Hospital Community in the Federal Capital Territory

Overview

Journal Cancer Control

Specialty Oncology

Date 2022 Feb 18

PMID 35180003

Authors

Oseremen I Aisuodionoe-Shadrach

Sefiu B Eniola

Maxwell M Nwegbu

Hadijat O Kolade-Yunusa

Oriaku O Okereke

Thairu Yunusa

Affiliations

Soon will be listed here.

Abstract

Background: Prostate cancer is the commonest cancer among men worldwide and serum prostate specific antigen (PSA) has remained the most commonly applied screening test for the disease till date. Current PSA test results guidelines in our population are informed by reference intervals derived from studies from Caucasians and other racial groups. With scanty data on PSA reference values from our local population, this study evaluated the serum PSA levels of apparently healthy Nigerian male subjects in whom prostate cancer and urinary tract infection have been excluded.

Method: This study had participants aged 40 to 70 years, with no lower urinary tract symptoms or other symptoms suggestive of prostate disease recruited from the male staff population of the University of Abuja and University of Abuja Teaching Hospital and the adjoining local community. They were physically examined, had prostate ultrasonography, urine analysis, and blood sample collected for PSA testing. Data collected was analyzed using Statistical Package for Social Science (SPSS) version 24.

Result: Of a total of 210 men who participated in the study, 191 eventually met the inclusion criteria. The average age was 52.9 years, ninety seven percent of them had heard of prostate cancer before now. The mean total PSA was 1.46 ng/mL (SD +/-1.55), while the reference interval was .23-5.60 ng/mL. The average prostate size was 41.8 mL (SD+/-20.11), and there was a positive correlation between the PSA and the prostate size (.418) as well as the age of the subjects (.446). There was no significant difference in the mean PSA value for those with or without family history of prostate cancer (=.979).

Conclusion: The reference range of PSA in Nigeria is higher than in other races, hence utilizing a local value in decision making would help to reduce unnecessary invasive procedures.

References

Bickers B, Aukim-Hastie C . New molecular biomarkers for the prognosis and management of prostate cancer--the post PSA era. Anticancer Res. 2009; 29(8):3289-98. View

Odedina F, Akinremi T, Chinegwundoh F, Roberts R, Yu D, Reams R . Prostate cancer disparities in Black men of African descent: a comparative literature review of prostate cancer burden among Black men in the United States, Caribbean, United Kingdom, and West Africa. Infect Agent Cancer. 2009; 4 Suppl 1:S2. PMC: 2638461. DOI: 10.1186/1750-9378-4-S1-S2. View

Badmus T, Adesunkanmi A, Yusuf B, Oseni G, Eziyi A, Bakare T . Burden of prostate cancer in southwestern Nigeria. Urology. 2010; 76(2):412-6. DOI: 10.1016/j.urology.2010.03.020. View

von Elm E, Altman D, Egger M, Pocock S, Gotzsche P, Vandenbroucke J . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007; 147(8):573-7. DOI: 10.7326/0003-4819-147-8-200710160-00010. View

Rebbeck T, Devesa S, Chang B, Bunker C, Cheng I, Cooney K . Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of african descent. Prostate Cancer. 2013; 2013:560857. PMC: 3583061. DOI: 10.1155/2013/560857. View

Amegbor K, Yao Seddoh T, Tengue K, Songne-Gnamkoulamba B, Napo-Koura G, JAMES K . [Epidemiology and histopronostic of prostatic cancer in Togo: about 202 cases diagnosed at the laboratory of pathology of the Tokoin teaching hospital of Lome]. Prog Urol. 2009; 19(2):112-5. DOI: 10.1016/j.purol.2008.10.008. View

Linnet K . Two-stage transformation systems for normalization of reference distributions evaluated. Clin Chem. 1987; 33(3):381-6. View

Ikuerowo S, Ajala M, Abolarinwa A, Omisanjo O . Age-specific Serum Prostate Specific Antigen Ranges Among Apparently Healthy Nigerian Men Without Clinical Evidence of Prostate Cancer. Niger J Surg. 2016; 22(1):5-8. PMC: 4785694. DOI: 10.4103/1117-6806.169821. View

Imai K, Ichinose Y, Kubota Y, Yamanaka H, Sato J . Diagnostic significance of prostate specific antigen and the development of a mass screening system for prostate cancer. J Urol. 1995; 154(3):1085-9. View

10.

Jackson M, Ahluwalia B, Herson J, Heshmat M, Jackson A, Jones G . Characterization of prostatic carcinoma among blacks: a continuation report. Cancer Treat Rep. 1977; 61(2):167-72. View

11.

Ikuerowo S, Omisanjo O, Bioku M, Ajala M, Mordi V, Esho J . Prevalence and characteristics of prostate cancer among participants of a community-based screening in Nigeria using serum prostate specific antigen and digital rectal examination. Pan Afr Med J. 2013; 15:129. PMC: 3830465. DOI: 10.11604/pamj.2013.15.129.2489. View

12.

Henderson R, Eastham J, Culkin D, Kattan M, Whatley T, Mata J . Prostate-specific antigen (PSA) and PSA density: racial differences in men without prostate cancer. J Natl Cancer Inst. 1997; 89(2):134-8. DOI: 10.1093/jnci/89.2.134. View

13.

Horn P, Pesce A . Reference intervals: an update. Clin Chim Acta. 2003; 334(1-2):5-23. DOI: 10.1016/s0009-8981(03)00133-5. View

14.

Schroder F . PSA screening--a review of recent studies. Eur J Cancer. 2009; 45 Suppl 1:402-4. DOI: 10.1016/S0959-8049(09)70065-6. View

15.

Zhang K, Bangma C, Roobol M . Prostate cancer screening in Europe and Asia. Asian J Urol. 2017; 4(2):86-95. PMC: 5717985. DOI: 10.1016/j.ajur.2016.08.010. View

16.

Pienta K . Critical appraisal of prostate-specific antigen in prostate cancer screening: 20 years later. Urology. 2009; 73(5 Suppl):S11-20. DOI: 10.1016/j.urology.2009.02.016. View

17.

Punglia R, DAmico A, Catalona W, Roehl K, M Kuntz K . Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med. 2003; 349(4):335-42. DOI: 10.1056/NEJMoa021659. View

18.

Bakir M, Abo-daher D . Age-specific reference ranges for prostate-specific antigen among healthy Syrian men. Int J Biol Markers. 2012; 27(2):e152-9. DOI: 10.5301/JBM.2012.9304. View

19.

Rabah D, Farhat K, Al-Atawi M, Arafa M . Age-Specific Reference Ranges of Prostate-Specific Antigen among Saudi Men as a Representation of the Arab Population. Med Princ Pract. 2019; 28(3):242-246. PMC: 6597911. DOI: 10.1159/000497744. View

20.

Prorok P, Andriole G, Bresalier R, Buys S, Chia D, Crawford E . Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials. 2001; 21(6 Suppl):273S-309S. DOI: 10.1016/s0197-2456(00)00098-2. View